Today's 29 articles span all four sections: AI-designed TROP2 mini-proteins and a mitochondria-targeted HDAC3 inhibitor, a clinical degrader's human ADME, free-energy uncertainty methods, and Third Rock's $2B Funnel pact plus AstraZeneca's Omniose buyout.
2026-11-11 · ⚗️HDAC3 (mitochondria-targeted small molecule) · Journal of Medicinal Chemistry (ACS)
- Attaching a TPP group to a classic HDAC pharmacophore steers HDAC3 inhibitors into mitochondria, where obesity-linked dysfunction disrupts fat burning.
- Structure-guided optimization yielded H18, a potent HDAC3 blocker that accumulates preferentially in mitochondria.
- In 3T3-L1 adipocytes, H18 limited lipid buildup, restored ATP and lowered oxidative stress.
- In diet-induced obese mice it cut weight gain and improved glucose handling, outperforming BG45.
💡 PointsBased on the abstractBefore I believed the phenotype is HDAC3 inhibition in mitochondria, I'd want a non-TPP analog and a TPP-linked inactive control: cationic TPP conjugates can themselves depolarize membranes and perturb respiration, which could mimic the ATP and oxidative-stress benefits. Also check isoform selectivity (HDAC1/2) and whether mitochondrial HDAC3 is the real target, plus tolerability and clearance of a lipophilic cation in chronic dosing.
📄 Paper · Journal of Medicinal Chemistry (ACS) ↗
2026-11-11 · ⚗️IRAK4/TYK2 dual PROTAC degrader · Journal of Medicinal Chemistry (ACS)
- A VAE-RNN generative model in the POLYGON framework explored chemical space between two unrelated kinase families, IRAK4 and TYK2.
- Iterative sampling, scoring and refocusing cycles avoided the limits of simple pharmacophore merging and produced a structurally novel spirocyclic scaffold.
- Water-site analysis with WaterMap guided optimization, and PROTAC conjugation then gave a dual degrader, C-8-014.
- The compound efficiently degrades both kinases, supporting a closed-loop AI design approach for hard-to-reach kinome regions.
💡 PointsBased on the abstractSpirocyclic cores are attractive for 3D character and IP space, but a dual IRAK4/TYK2 binder is only half the story here. The ATP pockets share little beyond the hinge, so I'd want biochemical affinity and kinome selectivity for the parent warhead before PROTAC conjugation, plus a non-degrading control. Degradation can also hide weak binding, so ternary complex and E3 dependence need checking, and so does synthetic tractability of the spirocycle.
📄 Paper · Journal of Medicinal Chemistry (ACS) ↗
2026-11-11 · ⚗️Penicillin-binding proteins 1 and 3 (C. difficile) · Journal of Medicinal Chemistry (ACS)
- Roughly a quarter of C. difficile patients relapse, because broad-spectrum first-line drugs wipe out protective gut bacteria.
- A nitroimidazole-based oxadiazole series is highly selective for C. difficile over commensal species, and the authors explain the chemical basis of that selectivity.
- The lead compound inhibits two penicillin-binding proteins that build the septal cell wall during division.
- In mice, genome sequencing showed the gut microbiome stayed intact, and the animals resisted C. difficile colonization.
💡 PointsBased on the abstractTwo PBPs as targets is the interesting bit: beta-lactam-like septal inhibition without a beta-lactam, and C. difficile is intrinsically tolerant of many of those. Before I got excited I'd want MICs against vancomycin- and fidaxomicin-comparator strains and a proper panel of anaerobic commensals, since nitroimidazoles are redox-activated and metronidazole-like off-target killing of Bacteroides is the obvious risk. Also check spore germination and recurrence after dosing stops.
📄 Paper · Journal of Medicinal Chemistry (ACS) ↗
2026-11-11 · ⚗️TROP2 mini-protein drug conjugate · Journal of Medicinal Chemistry (ACS)
- Deep-learning design produced a small protein binder against the tumor antigen TROP2, avoiding animal immunization and antibody screening.
- The binder showed good specificity and thermal stability, and partial diffusion sharpened its affinity by roughly sixty-fold.
- Attaching the microtubule-disrupting payload VcMMAE yielded mini-protein drug conjugates that selectively kill TROP2-positive cancer cells.
- Activity was assessed in cell lines, organoids and mouse xenografts.
💡 PointsBased on the abstractA de novo binder skips immunization, but an ADC carrier lives or dies on pharmacokinetics: without an Fc or albumin-binding handle, a mini-protein clears through the kidney fast, and a vcMMAE payload will raise renal and hydrophobicity-driven uptake concerns. I'd want half-life, kidney accumulation and TROP2-negative tissue data, plus a head-to-head against sacituzumab-type ADCs, before calling this an antibody replacement.
📄 Paper · Journal of Medicinal Chemistry (ACS) ↗
2026-11-03 · ⚗️PfSUB1 serine protease inhibitor · bioRxiv
- PfSUB1 is a parasite protease needed for merozoites to exit infected red blood cells, making it an attractive antimalarial target.
- Docking guided replacement of the P1-P2 dipeptide in peptidic boronic acids with a 3-aminomethylphenylboronic acid core, reducing peptide character.
- Adding a meta-carboxylate to engage Lys138 sharply boosted enzyme inhibition, and an N-acylsulfonamide swap kept comparable potency.
- Whole-parasite activity stayed modest, pointing to membrane permeability as the next hurdle.
💡 PointsBased on the abstractBoronic acids on a benzylamine core trade peptide-like recognition for a covalent warhead plus one salt bridge, so I'd want to know how much of the potency is just boron reactivity. Check selectivity against human serine proteases and run a non-boron control. The permeability problem is predictable: a carboxylate or acylsulfonamide next to a boronic acid is very polar, so test prodrug or ester masking early.
📄 Paper · bioRxiv ↗
2026-10-30 · ⚗️Glutaminyl cyclase (sQC/gQC) small-molecule inhibitors · European Journal of Medicinal Chemistry (Elsevier)
- Substrate-mimetic design guided by structure yielded a methylimidazolylethyl-pyrimidinamine series that hits both secretory and Golgi glutaminyl cyclases, which are zinc enzymes.
- The lead, compound 25, strongly stabilised both enzymes, and its co-crystal structure with sQC shows zinc binding plus a hydrogen bond to Gln 304, echoing how the natural substrate is recognised.
- In MDA-MB-231 breast cancer cells it cut pyroglutamylated CD47 at the surface while leaving total CD47 largely unchanged.
- It showed little activity across 14 other metalloenzymes, supporting selectivity.
💡 PointsBased on the abstractAn imidazole zinc-binder is the classic QC pharmacophore (PBD150 and the benzimidazole series), so the pyrimidinamine's novelty is mostly in the scaffold and its dual sQC/gQC reach. I'd want isoform potency separated from thermal stabilisation, since a shift is not Ki. Also missing: proof that pE-CD47 loss actually weakens CD47-SIRPα binding or boosts phagocytosis, plus cell permeability and metabolic stability of the imidazole.
📄 Paper · European Journal of Medicinal Chemistry (Elsevier) ↗
2026-10-16 · ⚗️AMPA receptor (GluA2) positive allosteric modulator · European Journal of Medicinal Chemistry (Elsevier)
- Researchers varied the 6-position of an oxathiazine-dioxide scaffold and picked a fluorinated analog, C17, as the best lead.
- Molecular dynamics suggested C17 grips the GluA2 ligand-binding domain dimer through hydrogen bonds, outperforming the clinical comparator TAK-653 and blocking desensitization.
- In stressed mice it showed antidepressant-like activity, and in rat hippocampal neurons it boosted AMPA currents without acting as an agonist itself.
- It also raised BDNF expression in a dose-dependent way.
💡 PointsBased on the abstractBeating TAK-653 in a GaMD simulation is a hypothesis, not evidence; I'd want a GluA2 LBD co-crystal or cryo-EM structure of C17 to confirm the dimer-interface H-bonds and the fluorine's role, plus a des-fluoro matched pair. The bigger question is the AMPA PAM liability: bell-shaped dose response, seizure and excitotoxicity margins, and brain exposure all need data before the BDNF and mouse behavior read as a window.
📄 Paper · European Journal of Medicinal Chemistry (Elsevier) ↗
2026-11-11 · 🧬Herbicide exposure / PTGS2 (COX-2) · Chemical Research in Toxicology
- A cross-sectional analysis of urinary 2,4-D in about 1,200 participants found a modest, borderline-significant association with prostate cancer after adjustment.
- Network toxicology, docking and expression data pointed to PTGS2 (COX-2) as a hub target; 2,4-D exposure raised PTGS2 and promoted proliferation and migration in prostate cancer cells.
- A COX-2 inhibitor reversed these effects in vitro.
💡 PointsBased on the abstractTreat this as hypothesis-generating. A cross-sectional odds ratio near the significance threshold cannot separate exposure from disease, and a single spot urine is a weak exposure measure. The in vitro dose is also worth checking against real human urinary levels. The COX-2 rescue is the interesting piece, but a docking-predicted binder plus a rescue experiment still isn't a mechanism; the next step is a cohort or an in vivo exposure model.
📄 Paper · Chemical Research in Toxicology ↗
2026-11-07 · 🧬RGS4 / Gαq/11 signaling · Biochemical Pharmacology
- RGS4 is a GTPase-activating protein that speeds GTP hydrolysis by Gαq/11 and so switches off GPCR-driven vascular tone, remodeling and inflammatory signaling.
- The review uses the RGS4 crystal structure to lay out its catalytic mechanism and contacts with Gαq/11 and PLCβ, and links the axis to hypertension and other cardiovascular disease.
- It surveys druggable features and the existing docking and MD studies of RGS4 inhibitors.
💡 PointsBased on the abstractRGS proteins are a classic hard target: the interface is a flat protein–protein contact, and most reported inhibitors are covalent or in silico only. The direction of therapy is also unclear, because boosting RGS4 would damp Gq signaling while inhibiting it would amplify it, and the cardiovascular case rests on which way disease tips. I'd ask for genetic human evidence and a validated tool compound before taking this beyond a review.
📄 Paper · Biochemical Pharmacology ↗
2026-11-06 · 🧬AR ligand-directed degrader (BMS-986365) / human ADME · Drug Metabolism and Disposition
- A radiolabel mass-balance study of the androgen receptor degrader BMS-986365 in healthy men combined an oral dose with an IV microtracer, so absorption and gut extraction could be separated.
- Oral bioavailability was low, driven partly by gut-wall metabolism, and elimination was almost entirely fecal with little renal excretion.
- One N-dealkylation-derived metabolite dominated circulating drug-related material, far above the parent; the two diastereomers were dosed and tracked separately.
💡 PointsBased on the abstractThat a single metabolite outweighs parent in plasma is the first thing I'd chase: does it keep AR-degrading activity, and was it covered in the tox species? Low bioavailability plus heavy gut-wall extraction also means food and CYP3A modulators could move exposure, so the DDI package matters more than for a typical oral small molecule. Degraders are rarely this well characterized in humans, so this is a useful benchmark.
📄 Paper · Drug Metabolism and Disposition ↗
2026-10-27 · 🧬Cetuximab / EGFR–ERK pathway · Biochemical Pharmacology
- Cetuximab is the only approved molecularly targeted agent against a tumor receptor in head and neck squamous cell carcinoma, yet response rates are low and resistance is common.
- The review groups resistance into EGFR alterations, compensatory parallel pathways and reactivation of PI3K/Akt and Ras/ERK signaling.
- It treats ERK as the integrator of genetic, epigenetic and adaptive resistance.
💡 PointsBased on the abstractFraming ERK as the convergence point is attractive because it suggests a common combination partner, but ERK reactivation is a readout of many upstream events and clinical ERK-pathway combinations have been hard to tolerate. The missing piece is patient-level data on which mechanism operates in which tumor. Without a biomarker that predicts the escape route, the combination trials will stay unselected.
📄 Paper · Biochemical Pharmacology ↗
2026-10-22 · 🧬Natural product (celastrol) / NCOR2–HDAC3 · Biochemical Pharmacology
- Celastrol cut viability of EBV-positive NK/T-cell lymphoma lines and slowed a short-term xenograft with more apoptosis markers.
- Chemical proteomics pulled down the corepressor NCOR2 near its deacetylase-activation domain; celastrol weakened NCOR2–HDAC3 association and inhibited recombinant HDAC3/NCOR2 activity.
- The result was shifted H3K27 acetylation, lipid-metabolic and stress transcriptional changes; an HDAC3 inhibitor partly reproduced them.
💡 PointsBased on the abstractCelastrol is a notoriously promiscuous electrophile, so a pull-down hit is where target validation starts, not ends. NCOR2 depletion partly changing the response helps, but an HDAC3 inhibitor only partially phenocopying says other targets are involved. I'd want a non-reactive analogue as a control, in vivo dosing beyond a short xenograft, and an exposure check, since celastrol's narrow therapeutic window is its long-standing problem.
📄 Paper · Biochemical Pharmacology ↗
2026-10-16 · 🧬Conventional chemotherapy / brain exposure · Biochemical Pharmacology
- The review argues many conventional cytotoxics retain real antitumor activity in glioblastoma but never reach sufficient intratumoral concentrations.
- It re-examines alkylators, microtubule agents, topoisomerase inhibitors and platinum compounds in terms of blood–brain barrier transport, uneven tumor distribution and systemic dose limits.
- Delivery strategies are presented as a way to restore these drugs without changing their pharmacology.
💡 PointsBased on the abstractThis is the right question to ask before another new-mechanism trial: was the target engaged at the tumor site? The catch is that the BBB is leaky in the contrast-enhancing core and intact at the invasive margin where recurrence starts, so total tumor concentration can mislead. I'd want unbound brain concentration and regional distribution data before crediting a delivery system, and the tolerability of higher exposure still has to be shown.
📄 Paper · Biochemical Pharmacology ↗
2026-10-16 · 🧬MCT1 / MCT4 transporters · Biochemical Pharmacology
- The review covers the proton-coupled transport mechanism, substrate recognition and chaperone-dependent trafficking of MCT1 and MCT4, and their distinct roles in tumor metabolic compartmentalization.
- It asks which cancers actually depend on lactate transport rather than just express the transporters.
- Inhibitors are grouped as nonselective, MCT1-selective, MCT4-selective or dual, and judged on potency, selectivity and translational evidence.
💡 PointsBased on the abstractThe useful distinction is expression versus functional dependence, because that decides patient selection. MCT1 inhibitors alone tend to be rescued by MCT4 upregulation, so dual inhibition or biomarker-defined MCT4-low tumors is the sensible design. I'd also watch the safety side: MCT1 sits in heart, muscle and the retina, and an exposure that blocks tumor lactate flux may hit normal tissue.
📄 Paper · Biochemical Pharmacology ↗
2026-11-11 · 💻Toxicity prediction / antimicrobial peptides (dataset and deep learning model) · Digital Discovery (RSC)
- Toxicity is a major obstacle to turning antimicrobial peptides into medicines, and existing prediction approaches suffer from scattered data and inconsistent annotation.
- The authors present CHAMP, a machine-readable collection of antimicrobial peptides, and AMPToxPred, a deep learning model for predicting peptide toxicity.
- Detail on model design, dataset size and benchmarking is not available from the public abstract, so this note covers only what is stated.
💡 PointsBased on the abstractThe dataset may matter more than the model. Peptide toxicity labels mix hemolysis, cytotoxicity and in vivo readouts across assays and cell types, so harmonizing them is real work. What I'd want to know is how sequence-similar peptides were split between train and test, and whether it beats a simple baseline on my own series. Without that, a good score tells me little.
📄 Paper · Digital Discovery (RSC) ↗
2026-11-11 · 💻Cheminformatics data mining / bioisosteric substituent replacement network · Journal of Chemical Information and Modeling (ACS)
- Substituent pairs are treated as bioisosteres when they appear in the same position of related compounds that act on the same target, and these pairs are linked into a network of interchangeable groups.
- Data come from compounds reported in the medicinal chemistry literature; the approach relies on co-occurrence in matching molecular contexts instead of similarity or property descriptors.
- It reflects substitutions chemists actually made and surfaces lesser-known replacements; the network is offered as a free web tool, with no experimental testing described.
💡 PointsBased on the abstractCo-occurrence mining encodes what chemists chose to make, not what worked: papers report successes, so the network inherits publication bias and says nothing about potency cliffs or ADME changes after a swap. Useful as an idea generator beyond a Topliss-style tree, but I'd want pairs ranked by measured activity deltas, not frequency, before trusting it on my series.
📄 Paper · Journal of Chemical Information and Modeling (ACS) ↗
2026-10-23 · 💻GNN virtual screening and repurposing / THRβ agonists (MASLD, dyslipidemia) · Journal of Chemical Information and Modeling (ACS)2026, 66 (21), 14215–14230
- A hierarchical pipeline chained a graph neural network screen, docking with free-energy rescoring, and molecular dynamics to look for structurally new THRβ agonists relevant to fatty liver disease.
- The tuned network beat conventional machine-learning baselines at ranking actives from an in-house compound library.
- Carvedilol emerged as a candidate; biochemical coactivator-recruitment and cell-based lipid assays supported partial agonism similar to the clinical comparator resmetirom, with simulations pointing to key pocket contacts.
💡 PointsBased on the abstractCarvedilol is an old beta-blocker, so a THRβ hit is intriguing but needs scrutiny. I'd want to see selectivity against THRα and cardiac liability, plus whether the activity needs concentrations far above those reached in patients. The GNN's gain over baselines also depends on the split; scaffold-based splitting would show whether it generalizes beyond the library.
📄 Paper · Journal of Chemical Information and Modeling (ACS) ↗
2026-10-22 · 💻Induced fit docking + FEP / ADMET anti-targets (CYP3A4, CYP2D6, hERG, PXR) · Journal of Chemical Theory and Computation (ACS)2026, 22 (21), 11687–11704
- Combines induced-fit docking with free energy perturbation to model flexible, promiscuous anti-target proteins: CYP3A4, CYP2D6, hERG and PXR.
- Imposing one shared binding pose across a congeneric series lets the workflow sample many receptor conformations efficiently.
- Evaluated retrospectively on public datasets and applied prospectively in ongoing drug discovery programs, supporting lead optimization away from off-target liabilities.
💡 PointsBased on the abstractThe consensus-pose assumption is both the trick and the risk: for hERG and CYP3A4, ligands in one series can flip modes, and a forced shared pose will quietly bias the ranking. I'd want to see a no-FEP baseline (ligand-based QSAR or simple docking) on the same sets, plus the cases where the pose failed. Prospective use is encouraging, but hit rate is unreported here.
📄 Paper · Journal of Chemical Theory and Computation (ACS) ↗
2026-10-22 · 💻Enhanced-sampling MD pocket discovery / c-MYC oncoprotein · Journal of Chemical Information and Modeling (ACS)2026, 66 (21), 14025–14037
- MYC, a largely disordered cancer driver long considered undruggable, was probed by combining conventional all-atom molecular dynamics with well-tempered metadynamics on a MYC motif in explicit salt water.
- Representative conformations from the sampled landscape displayed stable, ligand-accommodating pockets, and a known MYC inhibitor docked consistently with electrostatic features.
- Placed in several newly identified pockets, the inhibitor remained bound in long unbiased runs; support is purely computational, with no experimental test.
💡 PointsBased on the abstractA pocket that stays occupied in unbiased MD is weak evidence, since the ligand was placed there and a force field rarely ejects it. The real test is whether those states are populated: metadynamics free energies depend heavily on the collective variables and a disordered motif, and the force field matters a great deal for IDPs. I'd want NMR or SPR with mutants first.
📄 Paper · Journal of Chemical Information and Modeling (ACS) ↗
2026-10-21 · 💻Uncertainty quantification for enhanced-sampling free energy profiles / peptide-membrane interactions · Journal of Chemical Theory and Computation (ACS)2026, 22 (21), 11221–11232
- A generalized hierarchical Gaussian process treats hyperparameters and observation noise as uncertain rather than fixed, so error bars respond to how informative the data are.
- It was applied to umbrella sampling and extended Lagrangian metadynamics simulations of peptide-membrane interactions.
- Retrospective comparison showed the predicted uncertainties followed actual reconstruction errors across varied sampling and data conditions.
💡 PointsBased on the abstractMost of us report a free energy profile with a bootstrap bar and hope. Error bars that widen when sampling is thin would help separate a real barrier from noise. But the test here is retrospective, on peptide-membrane systems, where slow lipid relaxation breaks the usual assumptions. I'd want it checked against block averaging and replicate runs, and on a protein-ligand case, before trusting it.
📄 Paper · Journal of Chemical Theory and Computation (ACS) ↗
2026-10-16 · 💻Benchmark methodology / deep learning antibiotic screening evaluation · Journal of Chemical Information and Modeling (ACS)2026, 66 (21), 13703–13707
- A methodological commentary on evaluating deep learning models for antibiotic screening, where only a handful of compounds can be followed up.
- Because AUPRC shifts with how common actives are in the test set, and molecular splitting changes both structural similarity and class balance, a gap between splits cannot by itself show how much structure drove the change.
- The authors advise reporting test-set composition and split method, comparing models on one fixed independent set, and judging utility by top-ranked performance, early enrichment or prospective hit rates.
💡 PointsBased on the abstractAnyone who has watched a scaffold-split score drop knows the temptation to call it "generalization loss". Here the baseline moves too, since random AUPRC equals prevalence. A useful companion is a prevalence-matched or normalized comparison, plus hit rate at the few picks your assay budget allows. It is a commentary, so it offers no new benchmark.
📄 Paper · Journal of Chemical Information and Modeling (ACS) ↗
2026-11-11 · 🏢Trial result · Fierce Biotech · Beeline Medicines / Bristol Myers Squibb
- Beeline's Phase 2 trial of afimetoran, an oral TLR7/8 inhibitor licensed from Bristol Myers Squibb, met its primary endpoint in systemic lupus erythematosus.
- All three doses beat placebo on the SRI-4 response rate at week 48 in a dose-ranging study of adults on background therapy.
- No new safety signals were reported; Beeline plans pivotal trials in SLE and cutaneous lupus, with full data at a coming congress.
💡 PointsBased on public reportsA clean win at every dose is what Beeline needed to justify taking a drug BMS chose to shelve, and it validates the spin-out model for pipeline assets big pharma deprioritizes. The topline gave no effect sizes, though, and an SRI-4 gap over placebo has to be weighed against the other oral lupus entrants. Watch the dose-response shape and infection rates before pricing in a pivotal-trial success.
📰 Source · Fierce Biotech ↗
2026-11-11 · 🏢Restructuring · BioSpace · Capricor Therapeutics
- Capricor reduced its workforce by about 10% (roughly 23 people) and slowed work outside deramiocel, including its exosome platform.
- The FDA's target action date for the Duchenne cell therapy is November 22; an advisory committee earlier voted 9-3 against approval for the cardiomyopathy claim.
- The company has since narrowed its request to upper-limb function, where Phase 3 HOPE-3 met its primary endpoint, and is raising commercial manufacturing spend.
💡 PointsBased on public reportsThe company is concentrating every resource on one binary outcome while its activist shareholder pushes for capital preservation. The narrowed upper-limb request fits the HOPE-3 win, but the cardiac endpoint missed significance overall, so the label wording matters as much as approval itself. A rejection would leave a thin, one-asset company with few fallbacks.
📰 Source · BioSpace ↗
2026-11-11 · 🏢Regulatory approval · Fierce Pharma · Merck KGaA / Abbisko Therapeutics
- The FDA approved pimicotinib (Pimjetmi), an oral CSF-1R inhibitor discovered by Abbisko, for symptomatic tenosynovial giant cell tumor where surgery would cause functional limitation or severe morbidity.
- Approval rests on the Phase 3 MANEUVER trial and follows earlier clearances in China, Canada and Switzerland.
- Merck KGaA holds worldwide commercialization rights.
💡 PointsBased on public reportsThis is a China-originated asset reaching the US through a mid-cap European partner, which is a template other Chinese biotechs will study. In a small indication, differentiation will turn on liver safety: Turalio carries a boxed warning and a REMS, so a cleaner label would be the commercial lever. Pricing and prescriber habit against Ono's and Daiichi's products now decide uptake.
📰 Source · Fierce Pharma ↗
2026-11-10 · 🏢M&A · Fierce Biotech · AstraZeneca / Omniose
- AstraZeneca acquired Omniose, a preclinical biotech whose platform assembles conjugate vaccines inside an engineered cell rather than through multi-step chemistry.
- Omniose becomes a wholly owned subsidiary within AstraZeneca's infectious disease unit; financial terms were not disclosed.
- The two had collaborated on vaccines against drug-resistant bacteria since January 2024.
💡 PointsBased on public reportsBuying a partner you already work with is a classic de-risk-then-own move, and an undisclosed price suggests a small, platform-driven deal. Bacterial conjugate vaccines are where Pfizer and GSK are established, so the question is whether cell-based assembly is cheaper and more modular than chemical conjugation. Nothing clinical yet: this is a manufacturing and platform bet.
📰 Source · Fierce Biotech ↗
2026-11-10 · 🏢Restructuring · Fierce Biotech · Coherus BioSciences
- Coherus said it will reduce headcount by about 30% to narrow its focus on a Loqtorzi-based combination in esophageal cancer.
- Alongside the third-quarter report it cut full-year Loqtorzi guidance and flagged going-concern language, with cash runway under 12 months.
- It is not the first such cut: the company shed a similar share of staff last year after selling its Neulasta biosimilar.
💡 PointsBased on public reportsA second ~30% cut in two years, plus going-concern language, signals a company trading breadth for survival on a single PD-1 label that is stalling commercially. The esophageal combination becomes the whole thesis, so its next readout or partnering outcome is the real catalyst. Watch whether a partner or sale emerges before the runway forces a worse deal.
📰 Source · Fierce Biotech ↗
2026-11-10 · 🏢Trial result · Johnson & Johnson · Johnson & Johnson
- J&J said its second pivotal Phase 3 of Caplyta (lumateperone) in acute bipolar mania met the primary and key secondary endpoints.
- The first study read out in September; together they are intended to support a US submission for mania.
- Both trials ran three weeks, so maintenance efficacy and long-term safety are not addressed.
💡 PointsBased on public reportsTwo positive pivotal trials is what the FDA wants, and the second effect size was smaller than the first, which is worth noting for a label negotiation. Caplyta is a key piece of the Intra-Cellular deal, so this expands the addressable psychiatric market inside a crowded atypical-antipsychotic class. Differentiation will rest on tolerability versus metabolic burden rather than raw efficacy.
📰 Source · Johnson & Johnson ↗
2026-11-09 · 🏢Partnership · pharmaphorum · Third Rock Ventures / Funnel Biosciences
- Third Rock Ventures struck a partnership worth more than $2 billion with Funnel Biosciences (Fangnuo), a Chinese startup formed only months earlier.
- Funnel's platform pairs generative algorithms with physics-based energy functions to design epitope-guided antibodies from scratch.
- The company was co-founded in February by a former MSD executive and an AI protein-design researcher.
💡 PointsBased on public reportsA $2B headline on a months-old company is a biobucks number: expect the upfront to be a small fraction, and the value to depend on whether the platform yields developable molecules. It also shows a US venture builder sourcing AI discovery from China despite the political climate. The thing to check is how much is equity-like option value versus milestones payable on real clinical progress.
📰 Source · pharmaphorum ↗
2026-11-09 · 🏢Regulatory · Fierce Pharma · WuXi AppTec
- The Department of Defense delisted WuXi AppTec from its 1260H list of Chinese military companies, per a notice dated November 5.
- The company had been listed in June and sued; a court granted a preliminary injunction against enforcing the designation.
- The removal is without prejudice, so the Pentagon could relist it on other grounds.
💡 PointsBased on public reportsFor sponsors weighing CDMO exposure, this removes the most immediate trigger for BIOSECURE-style restrictions, and analysts treated it as a clear positive for the stock. But 'without prejudice' plus the earlier list-and-remove episode means supply-chain teams will keep dual-sourcing plans alive. The listing flip-flops are the real risk: customers price in policy volatility, not just today's status.
📰 Source · Fierce Pharma ↗
